ROS1 and non-small cell lung carcinoma: For the 1–2% of patients diagnosed with NSCLC positive for a ROS1 fusion (ROS1+), a current first-line therapy option, entrectinib, results in a disease response in the majority of patients with expected survival measured in years3.